Research and development daily Xinda Beval bead monoantin resistance has been approved in China for the treatment of relapsed glioblastoma

2020.12.28 Research and Development NEWS: Cyndabava bead monoantigen resistance approved for the treatment of relapsed glioblastoma in China; Vidixito single resistance approved by CDE breakthrough treatment; Ipaval monoantigen in China to be included in priority review; anti-HER2 dual-specific antibody KN026 and Aibo new joint drug treatment program approved clinical ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) "Drug Research and Development" Ganlai FXR agitator ASC42 completed the first phase I clinical trial in the United States subjects to the drug Ganlai Pharmaceuticals focused on the development and commercialization of innovative drugs in the field of non-alcoholic fatty hepatitis (NASH), is a wholly owned subsidiary of Goliath Pharmaceutical Co., Ltd. (HKEx Code: 1672).
announced today that its Farniol X-patient (FXR) astigtor, NASH candidate drug ASC42, has completed its first phase I clinical trial of the subject.
(Agency) (Drug Approval) Vidicyto monotherapy approved by CDE breakthrough treatment 28, Rongchang Biodeveloped antibody association drug (ADC) Vidimab vedotin (RC48-ADC) was officially awarded breakthrough therapy qualification by CDE.
are patients with localized late stage or metastatic urethra cancer (including bladder, urethra, kidney and urethra sources) who have progressed after failure of chemotherapy.
for the allergy, the FDA on September 21st granted Vidicido mono-breakthrough therapy approval.
(Medical Rubik's Cube) Ipaval monoantiton resistance in China to be included in the priority review! According to the latest publicity on the official website of CDE, the three emapalumab listing applications for Supi Pharmaceuticals are to be included in the priority review of "qualified approved drugs" for treatment in adults and children (newborns and above) with refractic, recurring or progressive diseases or insuperable to conventional HLH therapy for primary lymphocytosis (HLH) adults and children (newborns and above).
(Drug Mingkangde) micro-core bio-anti-tumor original innovative drug Theo Ronnie into the CDE "breakthrough treatment" micro-core biologics in the study of anti-tumor original innovative drug Chiauranib capsule was formally included in the CDE "breakthrough treatment drug varieties", into the adaptation market approval target confirmed phase III clinical trials for the treatment of patients with progression or recurrence of small cell lung cancer (SCLC) after the 2-line system chemotherapy program.
(US News Agency) Cyntafal bead monoantigen resistance in China was approved for the treatment of relapsed glioblastoma 28, Cyntaf announced its self-developed recombinant anti-VEGF humanized monoclonal antibody drug Dayo (Beval bead monoantigen, international trademark: Byvasda) officially obtained NMPA approval for the treatment of adult relapsed glioblastoma (GBM), which is the third adaptation approved by Davy.
was first approved for NMPA on June 17, 2020 for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer.
(Xinda Bio-announcement) People's Fu Pharmaceutical subsidiary Anli Shengtan tablets to obtain drug registration approval notice 28, People's Fu Pharmaceuticals subsidiary Wuhan People's Fu, the company holds 98.33 percent of its equity, holding subsidiary Yichang People's Fu Pharmaceutical Co., Ltd. holds 1.67 percent of its shares) recently received the State Drug Administration approved the issuance of Anlitan tablets of the "drug registration certificate."
(Sina Pharmaceutical News) Modern Pharmaceuticals: subsidiary 2 specifications of theacid saffentini injection to obtain a drug registration certificate modern pharmaceutical announcement, recently the company's wholly-owned subsidiary Guogong Limited received the Approval of the State Drug Administration issued the "sour scissine saffenite injection" 2 specifications of the drug registration certificate.
specifications: (1) 1 ml: 50 mg (by C22H30N2O2S) (2) 2 ml: 100 mg (by C22H30N2O2S).
(Modern Pharmaceutical Bulletin) East Sunshine: The subsidiary obtained the phosphate Emitaway capsule drug registration certificate East Sunshine announcement, the company's holding subsidiary Dongsian Pharmaceutical recently received the Approval of the State Drug Administration issued the "Drug Registration Certificate."
phosphate ethymethamivir is an oral direct anti-HCV drug, unstructic protein ("NS") 5A inhibitor.
(East Sunshine Announcement) Anti-HER2 dual-specific antibody KN026 and Aibo new joint drug treatment program approved clinical Corning Jerry Biopharmaceutical announced that the company has recently received the China National Drug Administration issued a drug clinical trial approval notice, approved to carry out K N026 combined with pyrethroids or KN026 in a joint with pyrithroids and fluvis groups for the treatment of her2-positive local late-stage non-excision and/or metastasis breast cancer that failed in the treatment of terpenes and yews.
(Agency)